Biopharmaceutical company Alkermes plc (Alkermes) recently announced it is accepting applications for its 3rd annual Alkermes Inspiration Grants program. The program awards upwards to $1 million to organizations for the implementation of innovative, high-impact, and replicable programs that positively impact people with mental health and addiction disorders.
According to Alkermes leadership, the program—which is accepting applications through October 2—highlights both the innovation that exists in the industry, as well as the lack of resources available for those with mental health needs. Specifically, the award grants from the program will seek to address two areas: the improvement of support for resources that help people affected by mental health and addiction disorders, and the integration of the perspective of people affected by such disorders into drug development and/or the delivery of care. Applications are available only to eligible U.S. 501(c)(3) non-profit organizations.
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis.
This was reported by Nasdaq on September 5, 2018.
Contact Information: Alkermes plc, 852 Winter Street, Waltham, Massachusetts 02451; (781) 609-6000; Website: www.alkermes.com